2017 American Society of Clinical Oncology Annual Meeting*

Download All
June 2-6, 2017; Chicago, Illinois
Jeffrey S. Weber, MD, PhD, reviews key skin cancer findings presented at the 2017 American Society of Clinical Oncology Annual Meeting.

Skin Cancer

Novel combination of IDO1 inhibitor and immune checkpoint inhibitor proves active in select solid tumors.

Released: June 9, 2017

In a phase II expansion study, the combination had a low incidence of grade 3/4 adverse events across all tumor types evaluated.

Released: June 5, 2017

A nearly 3-year follow-up confirmed superiority of pembrolizumab over ipilimumab in patients with advanced melanoma.

Released: June 5, 2017

First presentation of efficacy data suggests checkpoint inhibitor combination is effective in these patients, with intracranial ORR of 55%.

Released: June 7, 2017

Combination treatment doubled ORR vs ipilimumab alone with no unexpected toxicity.

Released: June 6, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue